Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

257 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-02

Study Completion Date

2017-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In oncology, anemia is a frequent symptom, leading to complication of patient management for, more or less, a long term but often poorly evaluated by medical teams.

In oncology, anemia is induced by multiple causes. Iron deficiency appears to be a leading cause of anemia, especially in people with solid cancer. Iron deficiency is characterized by a low level of iron . Iron is a trace element required for life. It is a major component of hemoglobin allowing the transport of oxygen in red blood cells. There are in fact 2 types of iron deficiency: an absolute iron deficiency with a deficiency of true iron and a functional iron deficiency. Since end of January 2014, intravenous iron-based injections have been reclassified for cancer patients at ICO Paul Papin. The monitoring of iron deficiency with or without anemia is currently done in our institute, the ICO-Paul Papin. There is a procedure for the management of anemia with or without iron deficiency but there is still no traceability of treatments performed, their compliance or even their impact on the rate hemoglobin and the quality of life of patients during their treatment. This observatory also makes it possible to evaluate the impact of this treatment on the quality of life of the patients and thus allows them a personalized care of the tiredness during their treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

NCT00224068

Anemia

COMPLETED PHASE4

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

NCT03933813

Epithelial Ovarian Cancer Anemia Iron Deficiency Anemia

TERMINATED PHASE1/PHASE2

Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy

NCT01101399

Iron-Deficiency Anemia

COMPLETED PHASE3

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

NCT00661999

Anemia Leukemia Lymphoma +4 more

COMPLETED PHASE3

Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients

NCT01168505

Breast Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is for patients with iron deficiency and / or anemia during treatment for cancer These patients will receive ferinject. Patients will perform functional assessments and complete quality of life questionnaires, when the ferinject will be injected, then at 1 month and 6 months.

Patients will be followed for 6 months in the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron Deficiency Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

cohort study

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm with Ferinject

Ferinject will be administered once at inclusion

Group Type EXPERIMENTAL

Ferinject

Intervention Type DRUG

Ferinject 50mg/ml, one injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ferinject

Ferinject 50mg/ml, one injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

carboxymaltose ferrique

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Patient with cancer regardless of the location
* Patient with specific treatment (chemotherapy +/- targeted therapy and / or radiotherapy, hormone therapy or surgery)
* Patient with Functional Iron Deficiency or absolute with or without anemia
* Having given written informed consent prior to any procedure related to the study.

Exclusion Criteria

* Patient in a palliative situation not receiving specific treatment for their cancer
* Patient is willing and able to comply with the protocol for the duration of the study including all scheduled treatment, visits and examinations
* Patient with myeloproliferative disease
* Contraindication to treatments for iron deficiency and / or anemia
* Pregnant woman, parturient or nursing mothers
* Patient has no valid health insurance
* Disorder precluding understanding of trial information or informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No